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Introduction: Solitary uterine metastases from extragenital cancers are very rare. Breast cancer is the most frequent
primary site of metastasis to the uterine corpus, with invasive lobular carcinoma more likely to spread to
gynecologic organs than invasive ductal carcinoma.
Case presentation: A 62-year-old postmenopausal Japanese woman was diagnosed with uterine leiomyomata
more than 20 years ago and had been managed conservatively until menopause. Seven years prior to her presentation,
she was diagnosed with breast cancer and underwent a partial resection of her right breast for stage IIA invasive lobular
carcinoma. She underwent adjuvant chemotherapy, radiotherapy, and five years of anastrozole hormonal therapy. She
presented with a growing uterine mass. Her tumor marker levels were markedly increased over the course of her follow-
up, but a systemic examination revealed only a solitary uterine tumor. She underwent a total abdominal hysterectomy
with bilateral salpingo-oophorectomy. A histopathological examination, including detailed immunohistochemistry,
confirmed metastatic invasive lobular carcinoma, infiltrating both her uterine myometrium and fibroid tissue.
Conclusion: We report a very rare metastatic pattern of invasive lobular carcinoma and demonstrate that gross cystic
disease fluid protein-15 and mammaglobin are useful in the diagnosis of metastatic breast cancer.
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The ovary and the vagina are the most frequent meta-
static sites for both extragenital and genital primary neo-
plasms, but it is very rare for extragenital cancers to
metastasize to the female reproductive tract [1]. Breast
cancer is the most frequent extragenital origin of metas-
tasis to the uterine corpus [2]; however, uterine involve-
ment remains very rare. The most common sites of
breast cancer metastasis are lung, bone, liver, and brain.
Most uterine metastases are found at the time of aut-
opsy [3] because uterine involvement by metastasis is a
sign of end-stage disease. When compared with invasive
ductal carcinoma (IDC) of the breast, the stage-matched* Correspondence: m-toyo@med.tohoku.ac.jp
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unless otherwise stated.prognosis is better for patients with invasive lobular car-
cinoma (ILC) [4]. However, ILC is more likely to spread
to gynecologic organs [5,6].
Anastrozole, a third-generation aromatase inhibitor,
has been shown to be superior to tamoxifen as adjuvant
therapy for patients with breast cancer [7]. In addition,
anastrozole is expected to be safer for the prevention of
recurrence and metastasis, because tamoxifen increases
the risk of endometrial cancer [8].
We report the case of a patient with enlarging uterine
fibroids after menopause. Seven years prior, she had
been treated for ILC with surgery, radiotherapy, and
anastrozole hormonal therapy. She underwent a total
hysterectomy, and a pathological examination at this
time revealed a solitary metastatic ILC lesion involving
the uterine myometrium and infiltrating a fibroid.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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A 62-year-old postmenopausal Japanese woman pre-
sented with a 23×12cm uterine mass. The mass was
growing, and our patient reported abdominal compres-
sion. She had first been diagnosed with uterine leiomyo-
mata more than 20 years previously and had taken
gonadotropin-releasing hormone agonist therapy for six
months. Her age at menopause was 51 years and at the
age of 55 years, she was diagnosed with breast cancer
and underwent a partial resection of her right breast. A
pathological examination of the neoplasm revealed ILC,
classified as pT2N1M0, stage IIA. Immunohistochemical
staining was positive for estrogen receptors, progester-
one receptors, and cerbB2, and 20% of the cells were
positive for Ki-67. She received adjuvant radiotherapy,
50 Gy to her right breast and an additional 10 Gy for lo-
calized irradiation. Our patient also underwent adjuvant
chemotherapy with six cycles of fluorouracil, epirubicin,
and cyclophosphamide. In addition, she took anastrozole
as hormonal therapy for five years after surgery.
Twenty months after the therapy ended, she was noted
to have elevated tumor markers (cancer antigen 15-3,
87.9IU/mL; carcinoembryonic antigen (CEA), 15.6ng/mL;
National Cancer Center stomach 439, 120IU/mL). A diag-
nostic workup was undertaken that included computed
tomography, magnetic resonance imaging (Figure 1a), and
transvaginal ultrasonography. Her uterus was irregularly
enlarged, measuring 23×12cm. Despite her postmeno-
pausal status, the uterine leiomyomata had markedly en-
larged since the previous examination two years prior. A
systemic examination, including technetium 99m hydroxy-
methylene diphosphonate bone scintigraphy, positron
emission tomography-computed tomography (Figure 1b),
and upper endoscopy, revealed no other lesions.(a)
Figure 1 Radiological images. (a) Pelvic magnetic resonance imaging, T2
tumor. (b) Positron emission tomography-computed tomography showingEndometrial sampling was technically impossible given the
size of the mass.
Our patient underwent a total abdominal hysterec-
tomy and bilateral salpingo-oophorectomy with the diag-
nosis of uterine malignancy, although it was unknown
whether the tumor was primary or metastatic. A patho-
logical examination revealed malignant cells with poor
epithelial staining, along with irregular nuclei; these cells
were infiltrating both her uterine fibroid tissue and her
myometrium (Figure 2a). There was a small nest of malig-
nant cells in the stroma of the atrophic endometrium. Im-
munohistochemical staining was positive for estrogen
receptors, cytokeratin AE1/AE3, anti-cytokeratin CAM5.2,
cluster of differentiation (CD) 10, CEA, cytokeratin (CK)
7, gross cystic disease fluid protein-15 (GCDFP-15), and
mammaglobin (Figure 2b). The tumor was negative for
progesterone receptors, CD45, myeloperoxidase, CD68,
chromogranin A, synaptophysin, CD56, vimentin, desmin,
smooth muscle actin, CK20, CDX-2, and E-cadherin. The
previous breast tissue specimens were also examined, and
malignant cells with a similar form to those seen in the
uterine tumor were observed (Figure 2c). The histopatho-
logical diagnosis was metastasis of breast ILC to both the
uterine leiomyoma and the myometrium. Our patient is
currently undergoing exemestane hormonal therapy and
remains without evidence of recurrent disease.
Discussion
ILC accounts for about 10% of breast cancer in female
patients [9]. The sites of metastatic spread in ILC differ
from those of IDC: in the latter, the common metastatic
sites are the lung, bones, liver, and brain; in ILC, the
gastrointestinal tract, peritoneum, retroperitoneum, and
gynecologic organs have been reported as metastatic(b)
-enhanced sagittal section, showing an irregularly enlarged uterine








Figure 2 Pathological microscopic examination. (a) Clusters of malignant epithelial cells infiltrate the uterine fibroma. Staining: hematoxylin
and eosin. Top left: magnified image of fibroid cells; bottom left: magnified image of carcinoma cells. (b) Immunohistochemical staining positive
for gross cystic disease fluid protein-15 (GCDFP-15) and mammaglobin. (c) Hematoxylin and eosin staining of the primary breast cancer specimen
demonstrates poor epithelial staining of the malignant cells with irregular nuclei. ILC, invasive lobular carcinoma.
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vant therapy than tamoxifen, especially for postmeno-
pausal patients with hormone-sensitive early breast cancer
[7]. The anticancer effects of anastrozole have also been
studied in endometrial cancers in a randomized pilot
study [10]. Despite the fact that there is a wide range of
metastatic sites possible in patients with ILC, it is ex-
tremely rare to see solitary uterine involvement after ana-
strozole therapy for the disease; just a few case reports
have been published in the English literature [11-13].
These reports emphasize the usefulness of GCDFP-15,
known for having high sensitivity and specificity for breast
cancer, as a tumor marker at the metastatic site [11-13]. In
our patient, the malignant epithelial cells within her uterusshowed poor epithelial staining and had little cytoplasm
and irregular nuclei. The pathological diagnosis was very
difficult on the basis of hematoxylin and eosin staining
alone: a wide differential diagnosis was possible, including
a blood-derived tumor, a neuroendocrine tumor, a sar-
coma, and small cell carcinoma. However, immunohisto-
chemistry positivity for cytokeratin, estrogen receptors,
progesterone receptors, GCDFP-15, and mammaglobin
gave definitive information by which we could make the
diagnosis of metastatic ILC to the uterus.
If metastatic infiltration involves the endometrial
glands, then abnormal uterine bleeding is often the first
symptom, and endometrial sampling allows the detec-
tion of malignant cells [14]. However, patients may often
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myometrium, as in our patient. When tumors metastasize
to the uterus, they involve only the myometrium in 64.5%
of cases, both the myometrium and the endometrium in
32.7%, and only the endometrium in just 3.8% [1]. Our pa-
tient presented with abdominal distension but without ab-
normal bleeding. Furthermore, a huge uterine fibroid
prohibited endometrial sampling. Hence, clinicians should
keep in mind that metastasis of malignant cells to the
uterus does not always result in ‘typical symptoms’ such as
abnormal genital bleeding.
Conclusions
We report a very rare metastatic pattern of ILC and
demonstrate that detailed immunohistochemistry, in-
cluding GCDFP-15 and mammaglobin, is useful in the
diagnosis of metastatic breast cancer. It is important for
clinicians to recognize that ILC and IDC have different
patterns of metastasis and that an isolated uterine me-
tastasis may occur after either anastrozole or tamoxifen
therapy. A comprehensive gynecologic workup should
be considered in patients with breast cancer who have
uterine lesions.
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